Published in
Wiley, Alimentary Pharmacology and Therapeutics, 8(44), p. 877-889, 2016
DOI: 10.1111/apt.13770
Links
- ORCID
- Wiley | PDF
- [boris.unibe.ch] | PDF
- [dx.doi.org] | PDF
- [hdl.handle.net] | PDF
- [hal.upmc.fr] | PDF
- [hal.upmc.fr] | PDF
- [hal.sorbonne-universite.fr] | PDF
- [hal.sorbonne-universite.fr] | PDF
- [boris.unibe.ch] | PDF
- [europepmc.org] | PDF
- [www.ncbi.nlm.nih.gov] | PDF
Tools
Diagnostic performance of FibroTest, SteatoTest and ActiTest in patients with NAFLD using the SAF score as histological reference
,
B. Varsat,
Q. Anstee,
M. Munteanu,
D. Tiniakos,
F. Charlotte,
M. Romero Gomez,
M. Trauner,
E. Bugianesi,
G. Marchesini,
C. Oliveira,
Ratziu
and other authors.
Full text: Download
Abstract
Other ; BACKGROUND: Blood tests of liver injury are less well validated in non-alcoholic fatty liver disease (NAFLD) than in patients with chronic viral hepatitis. AIMS: To improve the validation of three blood tests used in NAFLD patients, FibroTest for fibrosis staging, SteatoTest for steatosis grading and ActiTest for inflammation activity grading. METHODS: We pre-included new NAFLD patients with biopsy and blood tests from a single-centre cohort (FibroFrance) and from the multicentre FLIP consortium. Contemporaneous biopsies were blindly assessed using the new steatosis, activity and fibrosis (SAF) score, which provides a reliable and reproducible diagnosis and grading/staging of the three elementary features of NAFLD (steatosis, inflammatory activity) and fibrosis with reduced interobserver variability. We used nonbinary-ROC (NonBinAUROC) as the main endpoint to prevent spectrum effect and multiple testing. RESULTS: A total of 600 patients with reliable tests and biopsies were included. The mean NonBinAUROCs (95% CI) of tests were all significant (P